Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clin Cancer Res (2024) 30 (17): 3812–3823.

https://doi.org/10.1158/1078-0432.CCR-23-3981

Published: 03 September 2024

View article titled, Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Includes: Supplementary data

Journal Articles

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clin Cancer Res (2023) 29 (11): 2123–2130.

https://doi.org/10.1158/1078-0432.CCR-22-3497

Published: 01 June 2023

View article titled, Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Includes: Supplementary data

Journal Articles

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Arielle Elkrief, Alex Makhnin, Khadeja A. Moses, Linda S. Ahn, Isabel R. Preeshagul, Afsheen N. Iqbal, Sara A. Hayes, Andrew J. Plodkowski, Paul K. Paik, Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Franziska Michor, Helena A. Yu

Clin Cancer Res (2023) 29 (8): 1423–1428.

https://doi.org/10.1158/1078-0432.CCR-22-3484

Published: 14 April 2023

View article titled, Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Includes: Supplementary data

Journal Articles

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset

Christopher A. Febres-Aldana, Jason C. Chang, Ryan Ptashkin, Yuhan Wang, Erika Gedvilaite, Marina K. Baine, William D. Travis, Katia Ventura, Francis Bodd, Helena A. Yu, Alvaro Quintanal-Villalonga, W. Victoria Lai, Jacklynn V. Egger, Michael Offin, Marc Ladanyi, Charles M. Rudin, Natasha Rekhtman

Clin Cancer Res (2022) 28 (21): 4702–4713.

https://doi.org/10.1158/1078-0432.CCR-22-1115

Published: 01 November 2022

View article titled, Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset

Includes: Supplementary data

Journal Articles

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely

Clin Cancer Res (2021) 27 (10): 2920–2927.

https://doi.org/10.1158/1078-0432.CCR-20-4650

Published: 15 May 2021

View article titled, Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Includes: Supplementary data

Journal Articles

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Hira Rizvi, Andrew J. Plodkowski, Matthew D. Hellmann, Andrea Knezevic, Glenn Heller, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Gregory J. Riely

Clin Cancer Res (2021) 27 (8): 2209–2215.

https://doi.org/10.1158/1078-0432.CCR-20-4023

Published: 15 April 2021

View article titled, Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Journal Articles

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Helena A. Yu, Luis G. Paz-Ares, James Chih-Hsin Yang, Ki Hyeong Lee, Pilar Garrido, Keunchil Park, Joo-Hang Kim, Dae Ho Lee, Huzhang Mao, Sameera R. Wijayawardana, Ling Gao, Rebecca R. Hozak, Bo H. Chao, David Planchard

Clin Cancer Res (2021) 27 (4): 992–1002.

https://doi.org/10.1158/1078-0432.CCR-20-1690

Published: 15 February 2021

View article titled, Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Adam J. Schoenfeld, Joseph M. Chan, Daisuke Kubota, Hiroki Sato, Hira Rizvi, Yahya Daneshbod, Jason C. Chang, Paul K. Paik, Michael Offin, Maria E. Arcila, Monika A. Davare, Ujwal Shinde, Dana Pe'er, Natasha Rekhtman, Mark G. Kris, Romel Somwar, Gregory J. Riely, Marc Ladanyi, Helena A. Yu

Clin Cancer Res (2020) 26 (11): 2654–2663.

https://doi.org/10.1158/1078-0432.CCR-19-3563

Published: 01 June 2020

View article titled, Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

Includes: Supplementary data

Journal Articles

ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Pang-Dian Fan, Helena A. Yu

Clin Cancer Res (2018) 24 (22): 5499–5501.

https://doi.org/10.1158/1078-0432.CCR-18-2179

Published: 15 November 2018

View article titled, ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Journal Articles

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Ryan Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria Arcila, Gregory J. Riely, Marc Ladanyi

Clin Cancer Res (2018) 24 (13): 3108–3118.

https://doi.org/10.1158/1078-0432.CCR-17-2961

Published: 01 July 2018

View article titled, Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Includes: Supplementary data

Journal Articles

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

Kathryn C. Arbour, Emmett Jordan, Hyunjae Ryan Kim, Jordan Dienstag, Helena A. Yu, Francisco Sanchez-Vega, Piro Lito, Michael Berger, David B. Solit, Matthew Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria Arcila, Marc Ladanyi, Gregory J. Riely

Clin Cancer Res (2018) 24 (2): 334–340.

https://doi.org/10.1158/1078-0432.CCR-17-1841

Published: 15 January 2018

View article titled, Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Helena A. Yu, Alexander Spira, Leora Horn, Jared Weiss, Howard West, Giuseppe Giaccone, Tracey Evans, Ronan J. Kelly, Bhardwaj Desai, Andrew Krivoshik, Diarmuid Moran, Srinivasu Poondru, Fei Jie, Kouji Aoyama, Anne Keating, Geoffrey R. Oxnard

Clin Cancer Res (2017) 23 (24): 7467–7473.

https://doi.org/10.1158/1078-0432.CCR-17-1447

Published: 14 December 2017

View article titled, A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Includes: Supplementary data

Journal Articles

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Clin Cancer Res (2016) 22 (5): 1103–1110.

https://doi.org/10.1158/1078-0432.CCR-15-1031

Published: 29 February 2016

View article titled, Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Includes: Supplementary data

Journal Articles

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

Gregory J. Riely, Helena A. Yu

Clin Cancer Res (2015) 21 (10): 2221–2226.

https://doi.org/10.1158/1078-0432.CCR-14-3154

Published: 14 May 2015

View article titled, EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

Journal Articles

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Helena A. Yu, Gregory J. Riely, Christine M. Lovly

Clin Cancer Res (2014) 20 (23): 5898–5907.

https://doi.org/10.1158/1078-0432.CCR-13-2437

Published: 30 November 2014

View article titled, Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Journal Articles

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely

Clin Cancer Res (2013) 19 (8): 2240–2247.

https://doi.org/10.1158/1078-0432.CCR-12-2246

Published: 15 April 2013

View article titled, Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

NARROW

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas

Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer

ERBBal Remedies: Combination Therapy for EGFR-mutant Lung Cancers

Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer

A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

EGFR: The Paradigm of an Oncogene-Driven Lung Cancer

Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only